Company: EDSA
Filing Date: 2025-12-12
Form Type: 8-K
Source: 0001171843-25-007918
Chunk: 0

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On December 12, 2025, Edesa Biotech, Inc. (the “ Company”), filed a prospectus supplement (the “ Prospectus Supplement”) with the U. S. Securities and Exchange Commission (the “ SEC”) to increase the maximum aggregate offering amount of the Company’s common shares, without par value (the “ Common Shares”), issuable under the At The Market Offering Agreement (the “ ATM Agreement”) with H. C. Wainwright & Co., LLC, dated October 4, 2024, to $2,262,508. The Prospectus Supplement amends and supplements the information contained in the prospectus, dated September 9, 2025 (the “ Base Prospectus”), filed as part of the Company’s registration statement on Form S-3 (File No. 333-288966), as supplemented by the prospectus supplement dated September 9, 2025 (the “ Prior Prospectus”).

As of the date hereof, pursuant to the ATM Agreement, the Company has sold
an aggregate of $3,718,324.61 of Common Shares pursuant to the Prior Prospectus to date and an aggregate of $837,134 of Common Shares
pursuant to the prospectus supplement, dated October 4, 2024 to the Company’s Registration Statement on Form S-3 (333-266604).

Fasken Martineau DuMoulin LLP, counsel to the Company,
has issued a legal opinion relating to the validity of the $2,262,508 Common Shares that may be offered and sold pursuant to the ATM Agreement
and related Prospectus Supplement. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 to
this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute
an offer to sell or the solicitation of an offer to buy the Common Shares discussed herein, nor shall there be any sale of such securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.

Item 9.01 Financial Statements and Exhibits.